OBJECTIVE: To investigate the nature of cognitive impairments and underlying brain mechanisms in older female fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome (FXTAS). METHODS: Extensive neuropsychological testing and cognitive event-related brain potentials (ERPs; particularly, the auditory P300) were examined in 84 female participants: 33 fragile X premutation carriers with FXTAS (mean age = 62.8 years), 25 premutation carriers without FXTAS (mean age = 55.4 years), and 26 normal healthy controls (mean age = 59.3 years). RESULTS: Both premutation groups exhibited executive dysfunction on the Behavioral Dyscontrol Scale, with subtle impairments in inhibition and performance monitoring in female carriers without FXTAS, and more substantial deficits in FXTAS women. However, the female carrier group without FXTAS showed more pronounced deficiencies in working memory. Abnormal ERPs were recorded over the frontal lobes, where FXTAS patients showed both P300 amplitude reduction and latency prolongation, whereas only decreased frontal P300 amplitudes were found in carriers without FXTAS. These frontal P300 measures correlated with executive function and information processing speed. INTERPRETATION: The neuropsychological testing and ERP results of the present study provide support for the hypothesis that executive dysfunction is the primary cognitive impairment among older female premutation carriers both with and without FXTAS, although these deficits are relatively mild compared to those in FXTAS males. These findings are consistent with a synergistic effect of the premutation and aging on cognitive impairment among older female fragile X premutation carriers, even in those without FXTAS symptoms.
OBJECTIVE: To investigate the nature of cognitive impairments and underlying brain mechanisms in older female fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome (FXTAS). METHODS: Extensive neuropsychological testing and cognitive event-related brain potentials (ERPs; particularly, the auditory P300) were examined in 84 female participants: 33 fragile X premutation carriers with FXTAS (mean age = 62.8 years), 25 premutation carriers without FXTAS (mean age = 55.4 years), and 26 normal healthy controls (mean age = 59.3 years). RESULTS: Both premutation groups exhibited executive dysfunction on the Behavioral Dyscontrol Scale, with subtle impairments in inhibition and performance monitoring in female carriers without FXTAS, and more substantial deficits in FXTAS women. However, the female carrier group without FXTAS showed more pronounced deficiencies in working memory. Abnormal ERPs were recorded over the frontal lobes, where FXTAS patients showed both P300 amplitude reduction and latency prolongation, whereas only decreased frontal P300 amplitudes were found in carriers without FXTAS. These frontal P300 measures correlated with executive function and information processing speed. INTERPRETATION: The neuropsychological testing and ERP results of the present study provide support for the hypothesis that executive dysfunction is the primary cognitive impairment among older female premutation carriers both with and without FXTAS, although these deficits are relatively mild compared to those in FXTAS males. These findings are consistent with a synergistic effect of the premutation and aging on cognitive impairment among older female fragile X premutation carriers, even in those without FXTAS symptoms.
Authors: Sarah M Coffey; Kylee Cook; Nicole Tartaglia; Flora Tassone; Danh V Nguyen; Ruiqin Pan; Hannah E Bronsky; Jennifer Yuhas; Mariya Borodyanskaya; Jim Grigsby; Melanie Doerflinger; Paul J Hagerman; Randi J Hagerman Journal: Am J Med Genet A Date: 2008-04-15 Impact factor: 2.802
Authors: Jim Grigsby; Angela G Brega; Karen Engle; Maureen A Leehey; Randi J Hagerman; Flora Tassone; David Hessl; Paul J Hagerman; Jennifer B Cogswell; Rachael E Bennett; Kylee Cook; Deborah A Hall; Lanee S Bounds; Marsha J Paulich; Ann Reynolds Journal: Neuropsychology Date: 2008-01 Impact factor: 3.295
Authors: Elizabeth Berry-Kravis; Liane Abrams; Sarah M Coffey; Deborah A Hall; Claudia Greco; Louise W Gane; Jim Grigsby; James A Bourgeois; Brenda Finucane; Sebastien Jacquemont; James A Brunberg; Lin Zhang; Janet Lin; Flora Tassone; Paul J Hagerman; Randi J Hagerman; Maureen A Leehey Journal: Mov Disord Date: 2007-10-31 Impact factor: 10.338
Authors: Matthew F Pescosolido; Brian C Kavanaugh; Nathalie Pochet; Michael Schmidt; Beth A Jerskey; Jeffrey M Rogg; Philip L De Jager; Tracy L Young-Pearse; Judy S Liu; Eric M Morrow Journal: Mol Neuropsychiatry Date: 2019-03-06
Authors: J-C Yang; C Simon; A Schneider; A L Seritan; L Hamilton; P J Hagerman; R J Hagerman; J M Olichney Journal: Genes Brain Behav Date: 2013-12-26 Impact factor: 3.449
Authors: Jin-Chen Yang; Yu-Qiong Niu; Christa Simon; Andreea L Seritan; Lawrence Chen; Andrea Schneider; Shayan T Moghaddam; Paul J Hagerman; Randi J Hagerman; John M Olichney Journal: Neuropsychopharmacology Date: 2014-05-29 Impact factor: 7.853
Authors: Jim Grigsby; Kim Cornish; Darren Hocking; Claudine Kraan; John M Olichney; Susan M Rivera; Andrea Schneider; Stephanie Sherman; Jun Yi Wang; Jin-Chen Yang Journal: J Neurodev Disord Date: 2014-07-30 Impact factor: 4.025
Authors: Anne C Wheeler; Donald B Bailey; Elizabeth Berry-Kravis; Jan Greenberg; Molly Losh; Marsha Mailick; Montserrat Milà; John M Olichney; Laia Rodriguez-Revenga; Stephanie Sherman; Leann Smith; Scott Summers; Jin-Chen Yang; Randi Hagerman Journal: J Neurodev Disord Date: 2014-07-30 Impact factor: 4.025